Insider Selling: Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Sells 15,415 Shares of Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) Chairman Neil Desai sold 15,415 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $1.50, for a total value of $23,122.50. Following the completion of the transaction, the chairman now directly owns 1,236,128 shares in the company, valued at approximately $1,854,192. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Neil Desai also recently made the following trade(s):

• On Monday, August 5th, Neil Desai sold 5,652 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.34, for a total value of $7,573.68.
• On Monday, July 1st, Neil Desai sold 31,348 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.45, for a total value of $45,454.60.

Aadi Bioscience Trading Down 1.4 %

Shares of NASDAQ:AADI traded down $0.02 on Monday, reaching $1.38. 108,145 shares of the company traded hands, compared to its average volume of 289,717. The business’s 50-day simple moving average is $1.60 and its 200 day simple moving average is $1.83. Aadi Bioscience, Inc. has a 52 week low of $1.28 and a 52 week high of $7.24. The stock has a market capitalization of $33.88 million, a P/E ratio of -0.55 and a beta of 0.69.

Aadi Bioscience (NASDAQ:AADI) last posted its earnings results on Wednesday, May 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.02). The business had revenue of $5.35 million during the quarter, compared to the consensus estimate of $6.41 million. Aadi Bioscience had a negative return on equity of 61.83% and a negative net margin of 288.72%. Sell-side analysts expect that Aadi Bioscience, Inc. will post -2.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Aadi Bioscience in a research note on Tuesday, May 14th.

Institutional Trading of Aadi Bioscience

A number of hedge funds have recently made changes to their positions in AADI. Decheng Capital LLC bought a new position in Aadi Bioscience in the 4th quarter valued at approximately $1,063,000. Marquette Asset Management LLC bought a new position in Aadi Bioscience in the 1st quarter valued at approximately $135,000. Finally, Acuitas Investments LLC lifted its position in Aadi Bioscience by 10.8% in the 2nd quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock valued at $515,000 after acquiring an additional 34,344 shares in the last quarter. 52.08% of the stock is owned by institutional investors.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.